Filtered By:
Therapy: Statin Therapy
Nutrition: Diets

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 83 results found since Jan 2013.

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review
ConclusionConsumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
Source: Advances in Therapy - January 8, 2020 Category: Drugs & Pharmacology Source Type: research

Cardiovascular health of nonagenarians in southern Italy: a cross-sectional, home-based pilot study of longevity
Conclusion Nonagenarians and centenarians in the Cilento region had a healthy metabolic profile and a low prevalence of clinical cardiovascular disease. Even among nonagenarians and centenarians with structural heart abnormalities, report of symptoms is low. Larger studies in the Cilento population may help elucidate the mechanisms underlying cardiovascular health in the oldest old.
Source: Journal of Cardiovascular Medicine - January 14, 2020 Category: Cardiology Tags: Research articles: Epidemiology Source Type: research

The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Authors: Trivedi K, Le V, Nelson JR Abstract The high-purity eicosapentaenoic acid (EPA) prescription fish oil-derived omega-3 fatty acid (omega-3), icosapent ethyl (IPE), was recently approved by the United States Food and Drug Administration (FDA) for cardiovascular disease (CVD) prevention in high-risk patients. This approval is based on the 25% CVD event risk reduction observed with IPE in the pre-specified primary composite endpoint (cardiovascular [CV] death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) in the landmark Reduction of Cardio...
Source: Postgraduate Medicine - August 13, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research

Cardiovascular disease risk, awareness, and treatment in people with epilepsy
CONCLUSIONS: Participants with epilepsy had increased ASCVD risk, despite similar or better awareness, treatment, and control of individual risk factors such as diabetes and hypertension. Our results suggest that epilepsy is associated with numerous health behaviors leading to cardiovascular disease, though the causal pathway is complex as these variables (income, depression, diet, exercise, smoking) generally served as confounders rather than mediators.PMID:33690068 | DOI:10.1016/j.yebeh.2021.107878
Source: Epilepsy and Behaviour - March 10, 2021 Category: Neurology Authors: Samuel W Terman Carole E Aubert Chloe E Hill Jeremy Skvarce James F Burke Scott Mintzer Source Type: research

Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Circulation. 2021 Mar 29:CIR0000000000000961. doi: 10.1161/CIR.0000000000000961. Online ahead of print.ABSTRACTThis statement summarizes evidence that adverse pregnancy outcomes (APOs) such as hypertensive disorders of pregnancy, preterm delivery, gestational diabetes, small-for-gestational-age delivery, placental abruption, and pregnancy loss increase a woman's risk of developing cardiovascular disease (CVD) risk factors and of developing subsequent CVD (including fatal and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure). This statement highlights the importance of recognizing APOs...
Source: Circulation - March 29, 2021 Category: Cardiology Authors: Nisha I Parikh Juan M Gonzalez Cheryl A M Anderson Suzanne E Judd Kathryn M Rexrode Mark A Hlatky Erica P Gunderson Jennifer J Stuart Dhananjay Vaidya American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombos Source Type: research

Q & A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures
For Dr. Thomas Rando, the path to becoming a physician-scientist began with something that hedidn ’t learn in high school biology.After one class that touched on the connections between neurons and muscle fibers, Rando took it upon to himself to find all the information he could about how cells communicate through electrical signals.Soon, he began pursuing that interest at Harvard University, where he completed his undergraduate work, a doctorate in cell and developmental biology and his medical degree.Rando joined the neurology faculty at the Stanford University School of Medicine in 1995.There, he founded a clinic to t...
Source: UCLA Newsroom: Health Sciences - December 10, 2021 Category: Universities & Medical Training Source Type: news

RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
AbstractDiabetic dyslipidemia is characterised by low HDL-C and high triglyceride levels. Unlike the Caucasian population, though LDL-C levels are not very high, there is a preponderance of more atherogenic small, dense LDL particles among Indians. Furthermore, apo B levels are elevated. This, unique ‘atherogenic dyslipidemia’, is frequently encountered in South Asians with diabetes. People with type 2 diabetes are considered to be at high risk for vascular events. Hence, irrespective of other risk factors such as age, male gender, hypertension, family history, smoking, obesity, and polycyst ic ovary syndrome in women,...
Source: International Journal of Diabetes in Developing Countries - April 7, 2022 Category: Endocrinology Source Type: research

A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin
Conclusion The FDA proven indications of pitavastatin are primary dyslipidemia and mixed dyslipidemia as adjunctive therapy to dietary changes to lower total cholesterol, LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C. Pitavastatin might be suitable for subjects with diabetes, ACS (reduced revascularization), metabolic syndrome, CKD, HIV, and subjects with low levels of HDL-C. We highly recommend rational individualization for the selection of statin.PMID:35642121 | DOI:10.2174/2772432817666220531115314
Source: Pharmacological Reviews - June 1, 2022 Category: Drugs & Pharmacology Authors: Asim Ahmed Elnour Judit Don Azza Ramadan Adel Sadeq Abdulla Al Amoodi Kishore Gnana Sam Nadia Al Mazrouei Mohamed A Baraka Farah Hamad Farah Maisoun Alkaabi Source Type: research

What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever. The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news